Project Grant HT9425261E077
Award Date 5/1/26
Completion Date 6/30/28
Dollars Obligated $826K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02140, USA
Similar Awards
- Federal Grant Award Summary Award Details: Transposon Therapeutics, Inc. received a $1.92 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2026, with an ultimate completion date of February 14, 2028. The project, titled "Development of Human Line-1 Reverse Transcriptase Inhibitors for the Treatment of Amyotrophic Lateral Sclerosis," will be conducted in Laguna Niguel, California. Deliverables...
- The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...
- The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
- Federal Project Grant Award Summary Award Details: Modulo Bio, Inc. received a $1.74M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) with an award date of May 1, 2026, and a performance period through April 30, 2028. This administrative modification corrected the payment office DODAAC code for processing purposes without altering the award amount or other terms and conditions. Products and Services: Under this award,...
- This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...
- Federal Grant Award Summary The Defense Health Agency awarded Massachusetts General Hospital (MGH) a $839,954 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026 through May 31, 2028. This award funds research and development services for "Augmented Immunomodulatory and Neuroprotective Allogeneic B Cell Therapy for ALS," a two-year initiative focused on advancing therapeutic approaches for amyotrophic lateral sclerosis (ALS)....
- The Defense Health Agency awarded a $659,922 Project Grant to Macquarie University in Australia under the Military Medical Research and Development program (CFDA 12.420). The grant funds a gene therapy research project aimed at developing a treatment for delaying the onset of Amyotrophic Lateral Sclerosis (ALS) through nuclear TDP-43 supplementation. The research will be conducted at Macquarie University over a 2-year period from September 2025 to September 2027. This project grant is part of...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $839,999 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to develop a novel low-dose interleukin-2 (IL-2)-based regulatory T cell (Treg) combination therapy for amyotrophic lateral sclerosis (ALS). The award, effective September 1, 2026, through August 31, 2028, supports advanced biomedical research and translational development...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...